The participation of BCL-xL in resistance to treatment has been evidenced in multiple myeloma cells that co-express Bcl-2 and BCL-xL, which were resistant to treatment with venetoclax but were sensitive to treatment with the specific inhibitor of BCL-xL A-1155463. The gene discussed is BCL2L1; the disease is plasma cell myeloma.